Skip to content

Implementation and Evaluation of an Evidence Based Comprehensive Antimicrobial Stewardship Interventions in Blood Cancer Patients

Implementation and Evaluation of an Evidence Based Comprehensive Antimicrobial Stewardship Interventions in Haematological Malignancy Patients - NILL

Status
Recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/06/068904
Enrollment
153
Registered
2024-06-13
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C81- Hodgkin lymphoma Health Condition 2: C82- Follicular lymphoma Health Condition 3: C83- Non-follicular lymphoma Health Condition 4: C84- Mature T/NK-cell lymphomas Health Condition 5: C85- Other specified and unspecified types of non-Hodgkin lymphoma Health Condition 6: C86- Other specified types of T/NK-celllymphoma Health Condition 7: C88- Malignant immunoproliferative diseases and certain other B-cell lymphomas Health Condition 8: C90- Multiple myeloma and malignant pl

Interventions

Intervention1: Antibiotic policy specific to HM patients: Developed antibiotic policy will help in improving inappropriateness of antibiotic therapy (for 1 year) Control Intervention1: NA: NA

Sponsors

Avvaru Deepthi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All adults >=18 years of age diagnosed with HM on antibiotic. Prescribers involved with antibiotic prescription in the treatment of HM patients. Prescribers involved with antibiotic prescription in the treatment of HM patients, multidisciplinary (AMS) team

Exclusion criteria

Exclusion criteria: Pregnant and lactating women. Prescribers not involved with HM patients

Design outcomes

Primary

MeasureTime frame
To optimise antibiotic therapy through Antimicrobial Stewardship Intervention among Haematological Malignancy patients.Timepoint: After 6 months

Secondary

MeasureTime frame
Prospective audit & feedback by clinical pharmacist will aid in assessing & reducing potentially inappropriate therapy which will improve outcomes. Timepoint: After 6 months of intervention

Countries

India

Contacts

Public ContactDr Muralidhar Varma

Kasturba Medical College

muralidhar.varma@manipal.edu9845069639

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026